Efficacy

Learning clinical trial design? Efficacy endpoints, control groups and trial phases are part of the VIARES Clinical Research Associate course.

Every new medicine has to answer one question before anything else: does it work? In clinical research, the answer is called efficacy. Efficacy studies compare the new treatment with a control group under carefully managed conditions, so that any difference in outcome can be attributed to the treatment and not to chance, bias or the natural course of the disease.

This page explains the meaning of efficacy in research and pharmacology, how efficacy is measured and calculated, how it differs from effectiveness and efficiency, which trial phases generate efficacy data, and how the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) use that evidence.

Efficacy meaning and definition

The word efficacy comes from the Latin efficacia (“power to produce an effect”). In everyday English it simply means the capacity to produce a desired result. In clinical research the definition of efficacy is narrower: efficacy refers to the benefit an intervention produces under ideal conditions, in a selected population, with a standardized protocol and close follow-up.

Those ideal circumstances are deliberate. A placebo-controlled, randomized and blinded design minimizes bias, while strict eligibility criteria and monitored adherence reduce noise in the data. The result is high internal validity: if the trial shows a difference, you can be confident the treatment caused it. The price is lower external validity, because trial participants and trial conditions differ from everyday care.

Efficacy is always defined in relation to a specific primary outcome, a specific population and a specific comparator. “Drug X is efficacious” only means something when you add “for reducing hospitalization in adults with condition Y, compared with placebo, over 12 months.”

What does “efficacious” mean?

Efficacious is the adjective: an efficacious treatment is one that has shown efficacy, typically in a controlled clinical trial. You will also see the phrase “high efficacy”, which describes a large treatment effect on the primary endpoint. Note that “self-efficacy” in psychology is a different concept: it describes a person’s belief in their own ability to succeed and has nothing to do with drug efficacy.

Efficacy in pharmacology: efficacy vs potency

In pharmacology, efficacy has a precise meaning: the maximum response a drug can produce, regardless of dose. On a dose-response curve, efficacy is the height of the plateau (often written Emax). Potency is a different parameter: it describes how much drug is needed to reach a given effect, often expressed as the dose or concentration that produces 50 % of the maximum response.

• Efficacy = how big the effect can get (the ceiling of the curve).
• Potency = how little drug is needed to get there (the position of the curve on the dose axis).
• Pharmacokinetics (absorption, distribution, metabolism, excretion) and drug interactions influence how much drug actually reaches the receptor, so they shape the response a patient experiences.

Why is efficacy usually preferred over potency when comparing drugs? Because patients benefit from the size of the effect, not from the number of milligrams. A highly potent drug that reaches only a modest maximum response may be less useful than a less potent drug that achieves a larger one; a higher dose can compensate for lower potency, but not for lower efficacy.

Measuring efficacy in clinical trials

Measuring efficacy starts long before the first patient is enrolled. The protocol defines the clinical endpoint, the comparator, the sample size needed to detect a meaningful difference, and the statistical analysis. ICH E9 describes a confirmatory trial as an adequately controlled trial in which the hypotheses are stated in advance and evaluated, and notes that such trials are, as a rule, necessary to provide firm evidence of efficacy or safety.

The efficacy data are then summarized as an effect measure. For continuous endpoints (blood pressure, a symptom score) this is usually a difference in means. For event endpoints (stroke, infection, death) the most common measures are relative risk reduction, absolute risk reduction and number needed to treat. The primary analysis typically follows the intention-to-treat principle, with per-protocol analyses as supporting information.

Relative risk reduction, absolute risk reduction and NNT

Take an illustrative Phase III trial (hypothetical numbers) with 1,000 patients per arm. In the placebo arm, 100 patients (10 %) have a heart attack within two years; in the treatment arm, 60 patients (6 %) do.

The two numbers tell different stories. A 40 % relative reduction sounds impressive, but its practical value depends on baseline risk. That is why good trial reports and regulators look at absolute and relative measures together, along with confidence intervals.

Example: calculating vaccine efficacy

Vaccine efficacy (VE) uses the same logic. It is the proportional reduction in disease among vaccinated participants compared with unvaccinated (placebo) participants:

VE = (1 − RR) × 100, where RR = attack rate in the vaccine group / attack rate in the placebo group.

Illustrative example (hypothetical numbers): 10,000 participants receive the vaccine and 10,000 receive placebo. During follow-up, 20 vaccinated and 200 placebo participants develop the disease. The attack rates are 0.2 % and 2 %, so RR = 0.1 and VE = (1 − 0.1) × 100 = 90 %. Vaccine trials, including those for COVID-19 vaccines, usually express their primary efficacy result as a VE percentage with a confidence interval around the estimate.

Efficacy vs effectiveness vs efficiency

The difference between efficacy, effectiveness and efficiency is one of the most searched questions on this topic. The three terms describe different questions, and confusing them leads to wrong conclusions.

Effectiveness is usually lower than efficacy. In real-world practice patients are older, have more comorbidities, take other medications, miss doses and are followed less closely. As the primer by Singal and colleagues points out, poor access, acceptance and adherence rates can lead highly efficacious interventions to be less effective in practice than less-efficacious ones. Efficacy vs efficiency is a different comparison again: efficiency adds cost to the picture, so a treatment can be both efficacious and effective yet still not efficient.

Effectiveness research and comparative effectiveness

Effectiveness research asks how interventions perform for heterogeneous patient populations, with less-standardized treatment protocols and delivery in routine clinical settings. Comparative effectiveness research (CER) goes one step further and compares two or more existing options, for example two approved drugs, to inform clinical decisions. Effectiveness studies may also look at system-level factors that moderate outcomes, such as access, training of staff or follow-up intensity.

Efficacy trials and study design

Efficacy trials are built to isolate the effect of the intervention. Typical design features are randomization, a concurrent control group, blinding of patients and investigators, a pre-specified primary endpoint and a predefined analysis. The classic design is the randomized controlled trial with a placebo arm; ICH E10 explains when placebo, active, dose-comparison or other controls are appropriate.

Which phase of a trial is an efficacy trial? ICH E8(R1) groups studies by objective rather than by phase number:

• Exploratory studies (usually Phase II) investigate safety and efficacy in a selected patient population, refine the dose and regimen, and help select endpoints for later studies. Proof-of-concept studies sit here.
• Confirmatory studies (usually Phase III) confirm the preliminary evidence that a drug is safe and effective for the intended indication and population, and are often intended to provide an adequate basis for marketing approval.
• Phase I focuses mainly on safety, tolerability and pharmacokinetics, and Phase IV studies after approval often generate effectiveness and long-term safety data.

Not every efficacy trial is placebo-controlled. When an effective treatment already exists, a trial may compare the new drug with the standard and test superiority or use a non-inferiority design. Medical device and cancer screening studies follow the same principle, though blinding is often harder to achieve.

Efficacy and safety: how regulators decide

In the United States, the Food and Drug Administration approves a new drug when there is “substantial evidence” of effectiveness. Under 21 CFR 314.126, reports of adequate and well-controlled investigations provide the primary basis for that determination. The regulation lists the characteristics of such studies, including:

• a clear statement of objectives and methods of analysis in the protocol and study report;
• a design that permits a valid comparison with a control (placebo, dose-comparison, no-treatment, active or historical control);
• methods that minimize bias, such as randomization and blinding.

FDA’s revised draft guidance “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products” discusses the factors that affect the strength of evidence and clarifies how sponsors can rely on one adequate and well-controlled clinical investigation with confirmatory evidence. In the European Union, EMA’s Committee for Medicinal Products for Human Use (CHMP) assesses the application and recommends whether the medicine should be marketed; the European Commission then takes the legally binding decision. In both systems, efficacy is never judged alone: benefits are weighed against side effects and drug safety data.

Challenges and limitations in measuring efficacy

• Selected populations: strict inclusion criteria exclude many patients who will later receive the drug, so the target population may respond differently.
• Surrogate endpoints: a change in a lab value or imaging marker does not always translate into a health benefit for patients.
• Short follow-up: trials may be too short to show long-term efficacy or rare adverse events.
• Missing data and protocol deviations: dropouts, missed visits and assessments outside visit windows can bias the estimate.
• Placebo response and unblinding: subjective endpoints such as pain are sensitive to expectations.
• Interactions with other medications: excluded in trials, common in real-world practice.

Meta-analysis of several randomized controlled trials can increase precision, but it cannot fix flaws in the individual studies. Evidence-based medicine therefore combines efficacy data from controlled clinical trials with effectiveness data from practice when making informed decisions.

Efficacy synonyms and related terms

In general English, common synonyms for efficacy are effectiveness, efficaciousness, effectualness and power. In clinical research, however, no synonym is a perfect substitute:

• Effectiveness is not a synonym in trial language; it means performance in real-world conditions.
• Potency in pharmacology means the dose needed for an effect, not the size of the effect.
• Efficiency adds cost and resources.
• Evidence of efficacy and proof of concept describe the results that support moving a drug to the next stage of drug development.

FAQ

What does the term efficacy mean?

Efficacy means the ability of a treatment to produce its intended effect under ideal, controlled conditions. In clinical research it is shown in controlled clinical trials that compare the treatment with placebo or another control on a pre-specified endpoint. A treatment with proven efficacy can work; whether it works equally well in everyday care is a separate question of effectiveness.

What is another word for efficacy?

In everyday English, synonyms for efficacy include effectiveness, efficaciousness, effectualness and power. In clinical research, use these with care: effectiveness means performance in routine practice, and potency in pharmacology refers to the dose needed for an effect. When you mean benefit shown in a controlled trial, efficacy is the precise term.

What is the difference between efficacy, effectiveness and efficiency?

Efficacy asks whether an intervention can work under ideal, controlled conditions. Effectiveness asks whether it works in real-world clinical practice, with typical patients, adherence and settings. Efficiency asks whether the benefit justifies the cost and resources used. A treatment can be efficacious in a trial, less effective in practice and still not efficient if a cheaper option achieves similar results.

Which phase is an efficacy trial?

Efficacy is first explored in Phase II, where exploratory studies test whether the drug works in patients and refine the dose. Phase III confirmatory trials then provide the main evidence of efficacy and safety that supports marketing approval. Phase I focuses mainly on safety and pharmacokinetics, while Phase IV studies after approval add effectiveness and long-term safety data.

Can efficacy and effectiveness be used interchangeably?

Not in clinical research. Efficacy and effectiveness describe performance under different conditions: efficacy under the controlled conditions of a trial, effectiveness under the real-world conditions of routine care. Effectiveness is often lower than efficacy because of factors such as poor adherence, comorbidities and drug interactions. In everyday language the words overlap, but protocols, reports and regulatory documents keep them apart.

Sources

1. ICH E8(R1): General Considerations for Clinical Studies (ICH guideline)
2. ICH E9: Statistical Principles for Clinical Trials (ICH guideline)
3. ICH E10: Choice of Control Group and Related Issues in Clinical Trials (ICH guideline)
4. 21 CFR 314.126: Adequate and well-controlled studies (eCFR)
5. FDA: Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products (draft guidance)
6. European Medicines Agency: Authorisation of medicines
7. Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014 (NIH/NCBI PMC)
8. PRECIS-2: Pragmatic Explanatory Continuum Indicator Summary tool

Where you learn this at VIARES

Section 4, “Medicines Development Process and Good Clinical Practice (GCP)”, of the VIARES Clinical Research Associate course covers clinical development and regulatory submission; one of its learning outcomes is to describe the medicines development lifecycle and the significant stages in evaluating the efficacy and safety of new treatments. Section 6, “Clinical Trial Design & Clinical Research Roles and Responsibilities”, covers the study protocol, trial design and methodologies, and its assignment asks you to explain design choices such as stratified block randomization, double-dummy, cross-over and factorial designs and their bias-reducing effect. VIARES also offers a separate Micro Certificate EFFICACY: a knowledge check on this topic with unlimited attempts and an 80 % pass mark.